- AE
adverse event
- AKI
acute kidney injury
- AR
acute rejection
- ARD
absolute risk difference
- ARR
acute rejection rate
- ATG
anti-human thymocyte/antithymocyte (immune)globulin
- AZA
azathioprine
- BAS
basiliximab
- BEL
belatacept
- BENEFIT
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial
- BENEFIT-EXT
BENEFIT–Extended Criteria Donors
- BKV
BK virus
- BNF
British National Formulary
- BPAR
biopsy-proven acute rejection
- CCS
corticosteroid
- CEA
cost-effectiveness analysis
- CI
confidence interval
- CKD
chronic kidney disease
- CMU
Commercial Medicines Unit
- CMV
cytomegalovirus
- CNI
calcineurin inhibitor
- CRC
creatinine clearance
- CrI
credibility interval
- CSA
ciclosporin
- CVD
cardiovascular disease
- DAC
daclizumab
- DBD
donation after brain death
- DCD
donation after circulatory death
- DGF
delayed graft function
- DIC
deviance information criterion
- DWFG
death with functioning graft
- EBV
Epstein–Barr virus
- EC-MPS
enteric-coated mycophenolate sodium
- ECD
extended criteria donor
- eGFR
estimated glomerular filtration rate
- eMit
Electronic Market Information Tool
- EQ-5D
European Quality of Life-5 Dimensions (EuroQoL instrument)
- ESA
erythropoiesis-stimulating agent
- ESRD
end-stage renal disease
- EU
European Union
- EVL
everolimus
- GFR
glomerular filtration rate
- GP
general practitioner
- GRF
graft function
- HD
haemodialysis
- HLA
human leucocyte antigen
- HMGCoA
3-hydroxy-3-methylglutanyl-coenzyme A
- HR
hazard ratio
- HRG
Healthcare Resource Group
- HRQoL
health-related quality of life
- HTA
Health Technology Assessment
- ICDF
inconsistency degrees of freedom
- ICER
incremental cost-effectiveness ratio
- INHB
incremental net health benefit
- IQR
interquartile range
- IL2Mab
anti-interleukin-2 receptor monoclonal antibody
- ITT
intention to treat
- KTR
kidney transplant recipient
- MD
mean difference
- MDRD
Modification of Diet in Renal Disease
- ME
microemulsion
- MMF
mycophenolate mofetil
- MPA
mycophenolic acid
- MPS
mycophenolate sodium
- MTC
mixed-treatment comparison
- mTOR-I
mammalian target of rapamycin complex 1
- NHSBT
NHS Blood and Transplant
- NHS EED
NHS Economic Evaluation Database
- NICE
National Institute for Health and Care Excellence
- NMA
network meta-analysis
- NODAT
new-onset diabetes after transplant/transplantation
- OR
odds ratio
- PBO
placebo
- PCP
Pneumocystis jirovecii pneumonia
- PCR
polymerase chain reaction
- PD
peritoneal dialysis
- PenTAG
Peninsula Technology Assessment Group
- PNF
primary non-function
- PPP
purchasing power parity
- PRA
panel reactive antibody
- PSA
probabilistic sensitivity analysis
- PSS
Personal Social Services
- PTDM
post-transplant diabetes mellitus
- PTLD
post-transplant lymphoproliferative disorder
- QALY
quality-adjusted life-year
- rATG
rabbit anti-human thymocyte immunoglobulin
- RCT
randomised controlled trial
- RR
relative risk
- RRT
renal replacement therapy
- SE
standard error
- SRL
sirolimus
- TAC
tacrolimus
- TAC-PR
prolonged-release tacrolimus
- UKPDS
UK Prospective Diabetes Study
- USRDS
United States Renal Data System
- UTI
urinary tract infection
- WMD
weighted mean difference
